WO2014160390A1 - Therapeutic acid ceramidase compositions and methods of making and using them - Google Patents

Therapeutic acid ceramidase compositions and methods of making and using them Download PDF

Info

Publication number
WO2014160390A1
WO2014160390A1 PCT/US2014/026481 US2014026481W WO2014160390A1 WO 2014160390 A1 WO2014160390 A1 WO 2014160390A1 US 2014026481 W US2014026481 W US 2014026481W WO 2014160390 A1 WO2014160390 A1 WO 2014160390A1
Authority
WO
WIPO (PCT)
Prior art keywords
ceramidase
mixture
acid ceramidase
precursor
inactive
Prior art date
Application number
PCT/US2014/026481
Other languages
English (en)
French (fr)
Inventor
Edward H. Schuchman
Original Assignee
Icahn School Of Medicine At Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14/776,442 priority Critical patent/US9937246B2/en
Application filed by Icahn School Of Medicine At Mount Sinai filed Critical Icahn School Of Medicine At Mount Sinai
Priority to PL14775400T priority patent/PL2968479T3/pl
Priority to EP14775400.6A priority patent/EP2968479B1/en
Priority to JP2016502154A priority patent/JP6832158B2/ja
Priority to BR112015024538-2A priority patent/BR112015024538B1/pt
Priority to DK14775400.6T priority patent/DK2968479T3/da
Priority to EP19183045.4A priority patent/EP3659619A1/en
Priority to ES14775400T priority patent/ES2739811T3/es
Priority to MX2015012471A priority patent/MX2015012471A/es
Priority to CA2905449A priority patent/CA2905449A1/en
Publication of WO2014160390A1 publication Critical patent/WO2014160390A1/en
Priority to IL241390A priority patent/IL241390B/en
Priority to HK16108585.6A priority patent/HK1220399A1/zh
Priority to US15/909,609 priority patent/US10238721B2/en
Priority to US16/271,433 priority patent/US10918702B2/en
Priority to HRP20191361 priority patent/HRP20191361T1/hr
Priority to IL272214A priority patent/IL272214B/en
Priority to IL288427A priority patent/IL288427A/en
Priority to IL304629A priority patent/IL304629A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)

Definitions

  • This invention relates to therapeutic acid ceramidase compositions and methods of making and using them.
  • FD Acid ceramidase
  • AC Acid ceramidase
  • N-acylsphingosine deacylase I.U.B.M.B. Enzyme No. EC 3.5.1.23
  • the protein has been purified from several sources, and the human and mouse cDNAs and genes have been obtained (Bernardo et al., "Purification, Characterization, and Biosynthesis of Human Acid Ceramidase,” J. Biol. Chem. 270: 11098-102 (1995); Koch et al, "Molecular Cloning and Characterization of a Full-length Complementary DNA Encoding Human Acid Ceramidase. Identification of the First Molecular Lesion Causing Farber Disease," J. Biol. Chem.
  • Ceramide is a signaling lipid that is produced in response to various stimuli and extrinsic factors, including serum deprivation and treatment with many chemotherapy drugs, as well as in many human diseases (Hannun, "Function of Ceramide in Coordinating Cellular Responses to Stress,” Science 274: 1855-9 (1996); Spiegel et al, “Signal Transduction Through Lipid Second Messengers,” Curr. Opin. Cell. Biol. 8: 159-67 (1996)).
  • ceramide can influence growth and differentiation, regulate protein secretion, induce DNA fragmentation and apoptosis, and increase the synthesis and secretion of cytokines.
  • ceramide is rapidly produced at the cell surface, leading to membrane re-organization and downstream signaling that results in apoptosis.
  • AC and/or other ceramidases may then hydrolyze ceramide into the individual fatty acid and sphingosine components (Gatt, "Enzymic Hydrolysis and Synthesis of Ceramide,” J. Biol. Chem. 238:3131-3 (1963); Gatt, "Enzymatic Hydrolysis of Sphingolipids. 1. Hydrolysis and Synthesis of Ceramides by an Enzyme from Rat Brain,” J. Biol. Chem. 241 :3724-31 (1966); Hassler & Bell, “Ceramidase: Enzymology and Metabolic Roles,” Adv. Lip. Res. 26:49-57 (1993)).
  • ceramide degradation is the only source of intracellular sphingosine (Rother et al., "Biosynthesis of Sphingolipids: Dihydro ceramide and Not Sphinganine Is Desaturated by Cultured Cells," Biochem. Biophys. Res. Commun. 189: 14-20 (1992)), these enzymes may also be rate-limiting steps in determining the intracellular levels of this compound.
  • SIP sphingosine- 1 -phosphate
  • ceramidases can be "rheostats" that maintain a proper balance between cell growth and death (Spiegel & Merrill, "Sphingolipids Metabolism and Cell Growth Regulation,” FASEB J.
  • AC activity is regulated is the cleavage of the inactive precursor polypeptide into the active enzyme consisting of an alpha and beta subunit linked via disulfide bonds (Shtraizent et al., "Autoproteo lytic Cleavage and
  • a first aspect of the present invention relates to a therapeutic composition including a ceramidase mixture and a pharmaceutically acceptable carrier.
  • the ceramidase mixture includes an inactive acid ceramidase precursor and an active acid ceramidase.
  • a second aspect of the present invention relates to a method of acid ceramidase treatment, including formulating the acid ceramidase used in said treatment as a ceramidase mixture, where the ceramidase mixture includes an inactive acid ceramidase precursor and an active acid ceramidase.
  • a third aspect of the present invention relates to a method of producing a therapeutic composition.
  • the method includes providing a medium containing an inactive acid ceramidase precursor and incubating the medium under conditions effective to transform a portion of the inactive acid ceramidase precursor to active acid ceramidase.
  • the incubated medium is recovered as a ceramidase mixture comprising the inactive acid ceramidase precursor and an active acid ceramidase.
  • the present invention describes an optimal composition of recombinant AC
  • rAC inactive acid ceramidase
  • the present invention further describes the novel finding that, contrary to expectation, the fully active form of the enzyme is not the best form for promoting cell survival. Rather, preparations of purified rAC with higher amounts of inactive acid ceramidase (AC) precursor versus processed active AC are more effective at promoting cell survival and/or improving cell phenotype.
  • Two preparations of recombinant AC were obtained containing different ratios of precursor and active enzyme. They were then used to evaluate the effects on the survival of oocytes in culture. Contrary to expectation, the preparation containing a higher ratio of inactive precursor had a greater effect on cell survival. It is hypothesized that this is due to the fact that the fully active enzyme has a shorter half-life in cells and in cell culture media. The same two preparations were tested using cultured primary chondrocytes. As with the oocytes, the preparation of recombinant AC with less of the active form had a greater effect on the expression of collagen 2, a marker of
  • rAC is being used experimentally in a number of cell systems and animal models to slow ceramide-related cell death and/or improve the phenotype of cells used for cell transplantation. It is also being studied in several disease models.
  • the present invention describes the optimal preparation of rAC to be used for these purposes, which has numerous potential practical implications (e.g. , in vitro fertilization, cartilage repair, and cystic fibrosis treatment).
  • a novel method for the purification of recombinant AC was developed. In this method heat inactivation was used to remove acid sphingomyelinase and other contaminating proteins from the recombinant AC preparations.
  • Figures 1A-1C show that preparations of rAC with less active ceramidase perform better than those with more active ceramidase.
  • Figure 1 A is a western blot analysis showing the relative amounts of active (alpha/beta) versus inactive precursor rAC in two different bioreactor runs (Lot 6 and Lot 7).
  • Figure IB summarizes results showing the ability of Lots 6 and 7 to form healthy mouse embryos.
  • Figure 1C depicts results of Lot 6 and Lot 7 after testing using cultured rat chondrocytes. At two weeks, the amount of collagen 2 expression was analyzed using western blotting.
  • Figure 2 illustrates a time -response curve of AC and acid sphingomyelinase activity in Lot 7. Acid sphingomyelinase activity was removed without affecting AC activity.
  • Figure 3 is a plot of acid ceramidase activity in (nmol/ml/hour) versus incubation time (in days).
  • Figure 4 is a Western blot showing conversion of inactive acid ceramidase to active acid ceramidase.
  • Figures 5A-B are a Western blot showing conversion of inactive acid ceramidase to active acid ceramidase.
  • a first aspect of the present invention relates to a therapeutic composition including a ceramidase mixture and a pharmaceutically acceptable carrier.
  • the ceramidase mixture includes an inactive AC precursor and an active AC.
  • Ceramidases hydrolyze the amide linkage of ceramides to generate free fatty acids and sphingoid bases (Nikolova-Karakashian et al., "Ceramidases,” Methods Enzymol. 311 : 194— 201 (2000); Hassler et al, “Ceramidases: Enzymology and Metabolic Roles,” Adv. Lipid Res. 26:49-57 (1993), which are hereby incorporated by reference in their entirety). There are three types of ceramidases described to date (Nikolova-Karakashian et al., "Ceramidases," Methods Enzymol. 311 : 194-201 (2000), which is hereby incorporated by reference in its entirety). These are classified as acid, neutral, and alkaline ceramidases according to their pH optimum of enzymatic activity.
  • ACs have optimal enzymatic activity at a pH ⁇ 5.
  • the human AC was the first ceramidase to be cloned (Koch et al., "Molecular Cloning and Characterization of a Full-Length Complementary DNA Encoding Human Acid Ceramidase. Identification Of the First Molecular Lesion Causing Farber Disease," J. Biol. Chem. 271 :33110-33115 (1996), which is hereby incorporated by reference in its entirety). It is localized in the lysosome and is mainly responsible for the catabolism of ceramide.
  • Inactive AC precursors and active ACs suitable for use in the ceramidase mixtures of this and all aspects of the present invention can be homologous (i.e., derived from the same species) or heterologous (i.e., derived from a different species) to the tissue, cells, and/or subject being treated.
  • Ceramidase (e.g., AC) precursor proteins undergo autoproteolytic cleavage into the active form (composed of a- and ⁇ -subunits). The mechanism of human AC cleavage and activation is reported in Shtraizent et al., "Autoproteolytic Cleavage and Activation of Human Acid Ceramidase," J. Biol. Chem.
  • ceramidase as used herein includes both active ceramidases and ceramidase precursor proteins, where ceramidase precursor proteins are converted into active ceramidase proteins through autoproteo lytic cleavage.
  • Embodiments in which the precursor protein is taken up by the cell of interest and converted into active ceramidase thereby, as well as embodiments in which the precursor protein is converted into active ceramidase by a different cell or agent (present, for example, in a culture medium), are both contemplated.
  • AC (N-acylsphingosine deacylase, I.U.B.M.B. Enzyme No. EC 3.5.1.23) protein has been purified from several sources, and the human and mouse cDNAs and genes have been obtained. See Bernardo et al., "Purification, Characterization, and Biosynthesis of Human Acid Ceramidase," J. Biol. Chem. 270: 11098-102 (1995); Koch et al., "Molecular Cloning and Characterization of a Full-length Complementary DNA Encoding Human Acid Ceramidase. Identification of the First Molecular Lesion Causing Farber Disease," J. Biol. Chem.
  • AC protein [Homo sapien] (Accession No. AAC50907) is shown below in SEQ ID NO: 1.
  • the AC alpha subunit begins at the amino acid at position 22 and continues through position 142 (as shown in bold in SEQ ID NO: 1), while the beta subunit of the AC begins with the amino acid at position 143 and continues through position 395 (as shown in italics in SEQ ID NO: 1).
  • Active ACs and inactive AC precursor proteins that can be used in this and all aspects of the present invention include, without limitation, those set forth in Table 1 below.
  • Table 1 Exemplary Acid Ceramidase Family Members
  • the ceramidase mixture of the therapeutic composition may, in some
  • embodiments contain a greater amount of the inactive AC precursor than active AC.
  • the ceramidase mixture of the therapeutic composition may, in some instances, contain a lesser amount of inactive AC precursor than active AC.
  • an effective amount of the inactive AC precursor compared to the active AC in the mixture ranges from about 5 to 95 wt% of the inactive AC precursor and 95 to 5 wt% of the active AC; 20 to 80 wt% of the inactive AC precursor and 80 to 20 wt% of the active AC; 30 to 70 wt% of the inactive AC precursor and 70 to 30 wt% of the active AC; 40 to 60 wt% of the inactive AC precursor and 60 to 40 wt% of the active AC; 55 to 95 wt% of the inactive AC precursor and 45 to 5 wt% of the active AC; 70 to 95 wt% of the inactive AC precursor and 30 to 5 wt% of the active AC; and may alternatively range from 80 to 90 wt% of the inactive AC precursor and 20 to 10 wt% of the active AC.
  • an effective amount of the inactive AC precursor is 90 wt% while the active ceramidase is 10 wt% of the mixture.
  • An alternative embodiment may include 80 wt% of the inactive ceramidase precursor and 20 wt% of the active AC in the ceramidase mixture.
  • the ceramidase mixture may contain 60 wt% inactive ceramidase precursor and 40 wt% active ceramidase.
  • the therapeutic composition may also include pharmaceutically acceptable adjuvants, excipients, and/or stabilizers, and can be in solid or liquid form, such as tablets, capsules, powders, solutions, suspensions, or emulsions.
  • Suitable adjuvants include, but are not limited to, flagellin, Freund's complete or incomplete adjuvant, aluminum hydroxide, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsion, dinitrophenol, iscomatrix, and liposome polycation DNA particles.
  • a second aspect of the present invention relates to a method of AC treatment, including formulating the AC used in said treatment as a ceramidase mixture, where the ceramidase mixture includes an inactive AC precursor and an active AC.
  • treatment is carried out by introducing a ceramidase protein into the cells.
  • An approach for delivery of proteins or polypeptide agents ⁇ e.g., active ceramidase, inactive ceramidase precursor proteins) involves the conjugation of the desired protein or polypeptide to a polymer that is stabilized to avoid enzymatic degradation of the conjugated protein or polypeptide. Conjugated proteins or polypeptides of this type are described in U.S. Patent No. 5,681,811 to Ekwuribe, which is hereby incorporated by reference in its entirety.
  • the chimeric protein can include a ligand domain and the polypeptide agent ⁇ e.g., rAC, active AC, other ceramidase, inactive AC precursor protein, other ceramidase precursor proteins).
  • the ligand domain is specific for receptors located on a target cell.
  • Further embodiments of the present aspect relate to methods of treatment for a certain disease or disorder. These methods involve formulating the AC used in the treatment as a ceramidase mixture including an inactive ceramidase precursor and an active AC.
  • the disease or disorder is a joint disease or disorder and the ceramidase mixture according to the methods of the present invention is administered to a subject to treat the subject for the joint disease or disorder.
  • exemplary types of joint disease or disorders include, without limitation, osteoarthritis, rheumatoid arthritis, mucopolysaccharidosis, degenerative joint disease, joint injury, and Farber lipogranulomatosis.
  • the disease or disorder is a neurodegenerative disease or disorder and the ceramidase mixture according to the methods of the present invention is administered to a subject to treat the subject for the neurodegenerative disease or disorder.
  • neurodegenerative diseases or disorders include, without limitation, diabetes, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, and disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders, neurological disorders
  • Alzheimer's disease Frontotemporal Dementia, Dementia with Lewy Bodies, Prion disease, Parkinson's disease, Huntington's disease, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multiple System Atrophy, amyotrophic lateral sclerosis, inclusion body myositis, degenerative myopathy, spinocerebellar atrophy, metabolic neuropathy, diabetic neuropathy, endocrine neuropathy, orthostatic hypotension, brain injury, spinal cord injury, stroke, and motor neuron diseases such as spinal muscular atrophy.
  • the disease or disorder is a cardiac disease or disorder and the ceramidase mixture according to the methods of the present invention is administered to a subject to treat the subject for the cardiac disease or disorder.
  • cardiac diseases or disorders include, without limitation, heart disease, cardiac injury, atherosclerosis, thrombosis, cardiomyocyte apoptosis, hypercardia, heart infarction, mitral regurgitation, aortic regurgitation, septal defect, and tachycardia-bradycardia syndrome.
  • the disease or disorder is diabetes and the ceramidase mixture according to the methods of the present invention is administered to a subject to treat the subject for diabetes.
  • the disease or disorder is a pathogenic infection in a subject having cystic fibrosis, chronic obstructive pulmonary disease (COPD), and/or an open wound, and the ceramidase mixture according to the methods of the present invention is administered to a subject to treat the subject for the pathogenic infection.
  • pathogenic infections include, without limitation, viral, fungal, prionic, and bacterial.
  • Subjects suffering from cystic fibrosis, COPD, and/or an open wound may possess a high susceptibility for acquiring acute and/or chronic pathogenic infections, such as, e.g., bacterial, viral, fungal, protozoan, and/or prionic pathogenic infections.
  • Bacterial pathogens include, without limitation, Bacillus anthracis, Bordetella pertussis, Borrelia burgdorferi, Campylobacter jejuni, Chlamydia trachomatis, Clostridium botulinum, Clostridium tetani, Corynebacterium dipththeriae, Escherichia coli, enterohemorrhagic E.
  • Mycobacterium tuberculosis Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus spp., Pseudomonas aeruginosa, Rickettsia, Salmonella spp., Shigella spp., Staphylococcus spp., Staphylococcus aureus, Streptococcus spp., Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus B, Group A beta hemolytic Streptococcus, Streptococcus mutans, Treponema pallidum, Vibrio cholerae, and Yersinia pestis.
  • the pathogenic infection is a Pseudomonas infection.
  • Viral pathogens include, without limitation, RNA viruses, DNA viruses, adenovirdiae ⁇ e.g., mastadenovirus and aviadeno virus), herpesviridae ⁇ e.g., herpes simplex virus 1, herpes simplex virus 2, herpes simplex virus 5, and herpes simplex virus 6), leviviridae ⁇ e.g., levivirus, enter obacteria phage MS2, allolevirus), poxyiridae ⁇ e.g., chordopoxyirinae, parapoxvirus, avipoxvirus, capripoxvirus, leporipoxvirus, suipoxvirus, molluscipox virus, and entomopoxyirinae), papovaviridae ⁇ e.g., polyomavirus and papillomavirus), paramyxoviridae
  • paramyxovirus parainfluenza virus 1
  • mobillivirus such as measles virus, rubulavirus (such as mumps virus), pneumonoviridae ⁇ e.g., pneumovirus, human respiratory syncytial virus), metapneumovirus ⁇ e.g., avian pneumovirus and human metapneumo virus), picomaviridae ⁇ e.g., enterovirus, rhinovirus, hepatovirus such as human hepatitis A virus, cardiovirus, and apthovirus), reoviridae ⁇ e.g., orthoreo virus, orbivirus, rotavirus, cypo virus, fijivirus, phytoreo virus, and oryzavirus), retroviridae ⁇ e.g., mammalian type B retroviruses, mammalian type C retroviruses, avian type C retroviruses, type D retrovirus group, BLV-HTLV retroviruse
  • necleorhabdovirus arenaviridae ⁇ e.g., arenavirus, lymphocytic choriomeningitis virus, Ippy virus, and lassa virus), and coronaviridae ⁇ e.g., coronavirus and torovirus), Cytomegalovirus (mononucleosis), Dengue virus (dengue fever, shock syndrome), Epstein-Barr virus
  • Pathogenic fungi include, without limitation, the genera Aspergillus (e.g., Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus, Bacillus
  • Aspergillus fumigates Blastomyces, Candida (e.g., Candida albicans), Coccidiodes,
  • Pathogenic protozoan include, without limitation, Trypanosome spp., Leishmania spp., Plasmodium spp., Entamoeba spp., and Giardia spp. such as Giardia lamblia.
  • an "open wound” refers to a type of injury in which an epithelial layer, i.e., skin, is torn, cut, and/or punctured.
  • an open wound refers to a sharp injury which damages the dermis of the skin and concomitantly increases the chance of acquiring an infection.
  • the term "open wound” also encompasses burns.
  • the disease or disorder is an infection caused by ceramide accumulation and the ceramidase mixture according to the methods of the present invention is administered to a subject to treat the subject for the ceramide accumulation infection.
  • the present invention may, in other embodiments, be used to treat Farber disease.
  • treatment is carried out in vitro.
  • a ceramidase mixture can be taken from the subject or from a second subject then administered to the first subject (e.g., by injecting the mixture into the first subject).
  • treatment is carried out in vivo.
  • Mammalian subjects according to these aspects of the present invention include, for example, human subjects, equine subjects, porcine subjects, feline subjects, and canine subjects. Human subjects are particularly preferred.
  • any combination of active ceramidase, ceramidase precursor protein, and/or nucleic acid encoding ceramidase/ceramidase precursor protein can be administered.
  • Administration can be accomplished either via systemic administration to the subject or via targeted administration to affected tissues, organs, and/or cells.
  • the ceramidase mixture may be administered to a non- targeted area along with one or more agents that facilitate migration of the ceramidase mixture to (and/or uptake by) a targeted tissue, organ, or cell.
  • the ceramidase mixture itself can be modified to facilitate its transport to (and uptake by) the desired tissue, organ, or cell, as will be apparent to one of ordinary skill in the art.
  • the ceramidase mixture will be administered to a subject in a vehicle that delivers the ceramidase to the target cell, tissue, or organ.
  • a vehicle that delivers the ceramidase to the target cell, tissue, or organ.
  • administration include, without limitation, orally, by inhalation, intratracheal inoculation, aspiration, airway instillation, aerosolization, nebulization, intranasal instillation, oral or nasogastric instillation, intraperitoneal injection, intravascular injection, topically, transdermally, parenterally, subcutaneous ly, intravenous injection, intra-arterial injection (such as via the pulmonary artery), intramuscular injection, intrapleural instillation, intraventricularly, intralesionally, intrathecally, by application to mucous membranes (such as that of the nose, throat, bronchial tubes, genitals, and/or anus), or implantation of a sustained release vehicle.
  • inhalation intratracheal inoculation
  • aspiration airway instillation
  • aerosolization nebulization
  • nebulization intranasal instillation
  • oral or nasogastric instillation intraperitoneal injection
  • the ceramidase mixture is administered orally, topically, intranasally, intraperitoneally, intravenously, subcutaneously, or by aerosol inhalation. In some embodiments, the ceramidase mixture is administered via aerosol inhalation. In some embodiments, the ceramidase mixture can be incorporated into pharmaceutical compositions suitable for administration, as described herein.
  • the ceramidase mixture may be orally administered, for example, with an inert diluent, or with an assimilable edible carrier, or they may be enclosed in hard or soft shell capsules, or they may be compressed into tablets, or may be incorporated directly with the food of the diet.
  • the ceramidase mixture may be incorporated with excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, and the like.
  • Such compositions and preparations should contain at least 0.1% of ceramidase.
  • the percentage of ceramidase mixture in these compositions may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit.
  • the amount of the ceramidase mixture in such therapeutically useful compositions is such that a suitable dosage will be obtained.
  • the tablets, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a binder such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a binder such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a binder such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a binder such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a binder such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a binder such as gum
  • disintegrating agent such as corn starch, potato starch, or alginic acid
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose, or saccharin.
  • a liquid carrier such as fatty oil.
  • the ceramidase mixture may also be administered parenterally.
  • Solutions or suspensions of ceramidase can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils.
  • Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil.
  • water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
  • the ceramidase mixture may also be administered directly to the airways in the form of an aerosol.
  • ceramidase in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants.
  • suitable propellants for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants.
  • the ceramidase mixture may also be administered in a non-pressurized form.
  • Exemplary delivery devices include, without limitation, nebulizers, atomizers, liposomes (including both active and passive drug delivery techniques) (Wang et al, "pH-
  • Administration can be carried out as frequently as required and for a duration that is suitable to provide effective treatment.
  • administration can be carried out with a single sustained-release dosage formulation or with multiple daily doses.
  • Treatment according to this and all aspects of the present invention may be carried out in vitro or in vivo.
  • In vivo treatments include, for example, embodiments in which the population of cells is present in a mammalian subject.
  • the population of cells can be either autologous (produced by the subject), homologous, or heterologous.
  • Suitable subjects according to these embodiments include mammals, e.g., human subjects, equine subjects, porcine subjects, feline subjects, and canine subjects.
  • one or more additional agents which reduce ceramide levels may be administered with the ceramidase mixture.
  • the effective amount of a therapeutic agent/cell population of the present invention administered to the subject will depend on the type and severity of the disease or disorder and on the characteristics of the individual, such as general health, age, sex, body weight, and tolerance to drugs. It will also depend on the degree, severity, and type of disease or disorder. The skilled artisan will be able to determine appropriate dosages depending on these and other factors.
  • the method includes treating one or more mammalian cells ex vivo with said ceramidase mixture to promote cell survival.
  • Cells whose survival can be promoted according to this aspect of the present invention include, without limitation, those that utilize the ceramidase apoptosis pathway, which includes a wide variety of cells (Obeid et al, "Programmed Cell Death Induced by Ceramide," Science
  • hepatocytes e.g., hepatocytes (Arora et al., "Ceramide Induces Hepatocyte Cell Death Through Disruption of Mitochondrial Function in the Rat," Hepatol. 25:958-63 (1997), which is hereby incorporated by reference in its entirety), skin fibroblasts (Mizushima et al., "Ceramide, a Mediator of Interleukin 1, Tumour Necrosis Factor a, as Well as Fas Receptor Signalling, Induces Apoptosis of Rheumatoid
  • Preferred cell types are eggs (fertilized or unfertilized), embryos, primary cells ⁇ e.g., neurons), sperm, synovial fibroblasts, and embryonic stem cells.
  • the ceramide apoptosis pathway appears to be conserved across mammalian species (Lee & Amoscato, "TRAIL and Ceramide,” Vitam. Horm. 67:229-55 (2004); see also, Samadi,
  • suitable cells include those of humans, monkeys, mice, rats, guinea pigs, cows, horses, sheep, pigs, dogs, and cats. This method may also be used to prolong the survival of eggs and/or embryos during in vitro fertilization procedures, facilitating the identification and selection of healthy embryos for reimplantation, especially for older human women and for veterinary breeding procedures.
  • Cells according to this aspect of the present invention can be provided by methods that will be apparent to the skilled artisan.
  • the cells can be obtained from an animal or from an existing ex vivo source ⁇ e.g., a tissue sample, a cell culture, etc.) using standard techniques.
  • Treating cells ex vivo includes treating cells present in a homogeneous culture, as well as cells present in a heterogeneous culture ⁇ e.g., a tissue sample).
  • Inactive AC precursors and active ACs that can be used to prepare the ceramidase mixture in this and all aspects of the present invention include, without limitation, those set forth in Table 1, supra.
  • the AC can be homologous (i.e., derived from the same species) or
  • heterologous i.e., derived from a different species
  • One embodiment of the present aspect of AC treatment relates to a method of producing chondrocytes with the ceramidase mixture. This method involves selecting a population of cells having the potential to differentiate into chondrocytes and treating the selected cell population with the ceramidase mixture to transform one or more of the cells in the selected population into chondrocytes.
  • Cells having the potential to differentiate into chondrocytes include bone marrow cells, fibroblasts, mesenchymal stem cells, and/or fibroblasts (see Mizushima et al, "Ceramide, a Mediator of Interleukin 1, Tumour Necrosis Factor a, as Well as Fas Receptor Signaling, Induces Apoptosis of Rheumatoid Arthritis Synovial Cells," Ann. Rheum. Dis. 57:495-9 (1998), which is hereby incorporated by reference in its entirety).
  • Chondrocytes include, without limitation, articular chondrocytes, nasal chondrocytes, tracheal chondrocytes, meniscal chondrocytes, and aural chondrocytes. These include, for example, mammalian chondrocytes, e.g., human chondrocytes, equine chondrocytes, porcine chondrocytes, feline chondrocytes, and canine chondrocytes.
  • the chondrocytes are primary chondrocytes.
  • Suitable cells include mammalian cells, e.g., human cells, equine cells, porcine cells, feline cells, and/or canine cells. Human cells are particularly preferred.
  • the ceramidase mixture and methods of treating the populations of cells with ceramidase mixture include all those set forth supra.
  • Another embodiment of the present aspect of AC treatment relates to a method of promoting chondrogenesis with the ceramidase mixture.
  • this method further includes selecting a population of stem cells in need of differentiation into chondrocytes, treating the population of stem cells with the ceramidase mixture to enrich mesenchymal stem cells within the stem cell population, and treating the population of enriched mesenchymal stem cells with the ceramidase mixture to promote differentiation of mesenchymal stem cells into chondrocytes.
  • Suitable cells populations include mammalian cells populations, e.g., human cells populations, equine cells populations, porcine cells populations, feline cells populations, and/or canine cells populations. Human cells populations are particularly preferred.
  • Suitable stem cells include bone marrow cells, adipocytes, and skin cells. Additional stem cells according to this aspect of the present invention include, without limitation, embryonic stem cells, somatic stem cells, induced pluripotent stem cells, totipotent stem cells, pluripotent stem cells, and multipotent stem cells. Exemplary stem cells include, for example, hematopoietic stem cells, mesenchymal stem cells, neural stem cells, endothelial progenitor cells, epithelial stem cells, epidermal stem cells, adipocytes, and cardiac stem cells. Suitable stem cells include, but are not limited to, mammalian cells, e.g., human, equine, porcine, feline, and canine bone marrow cells, adipocytes, and skin cells. Human cells are particularly preferred.
  • Suitable chondrocytes are consistent with those described supra. The
  • differentiated mesenchymal stem cells may, alternatively, be primary cells such as, but not limited to, neurons, hepatocytes, bone cells, lung cells, and cardiac cells.
  • the number of differentiated cells in the cell population is maintained. In at least one embodiment, the number of differentiated cells in the cell population is increased. As will be apparent to the skilled artisan, maintaining or increasing the overall number of differentiated cells in the population can be achieved by decreasing or preventing de-differentiation of cells in the population that are already differentiated, by stimulating the differentiation of undifferentiated cells in the population, or both.
  • the ceramidase mixture and methods of treating the populations of cells with ceramidase mixture include all those set forth supra.
  • a third aspect of the present invention relates to a method of producing a therapeutic composition.
  • the method includes providing a medium containing an inactive AC precursor; incubating the medium under conditions effective to transform a portion of the inactive AC precursor to active AC; and recovering the incubated medium as a ceramidase mixture comprising the inactive AC precursor and an active AC.
  • the therapeutic composition of the present invention contains a recombinant protein including both inactive AC precursor and active AC.
  • the recombinant protein of the present invention may be prepared for use in the above described methods of the present invention using standard methods of synthesis known in the art, including solid phase peptide synthesis (Fmoc or Boc strategies) or solution phase peptide synthesis.
  • proteins of the present invention may be prepared using recombinant expression systems.
  • the use of recombinant expression systems involves inserting the nucleic acid molecule encoding the amino acid sequence of the desired peptide into an expression system to which the molecule is heterologous (i.e., not normally present).
  • One or more desired nucleic acid molecules encoding a peptide of the invention may be inserted into the vector.
  • the multiple nucleic acid molecules may encode the same or different peptides.
  • the heterologous nucleic acid molecule is inserted into the expression system or vector in proper sense (5'— 3') orientation relative to the promoter and any other 5' regulatory molecules, and correct reading frame.
  • nucleic acid constructs can be carried out using standard cloning procedures well known in the art as described by Joseph Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL (Cold Springs Harbor 1989).
  • U.S. Patent No. 4,237,224 to Cohen and Boyer which is hereby incorporated by reference in its entirety, describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced by means of transformation into a suitable host cell.
  • a variety of genetic signals and processing events that control many levels of gene expression can be incorporated into the nucleic acid construct to maximize peptide production.
  • mRNA messenger RNA
  • any one of a number of suitable promoters may be used. For instance, when cloning in E.
  • promoters such as the T7 phage promoter, lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, the P R and P L promoters of coliphage lambda and others, including but not limited, to lac ⁇ JV5, ompF, bla, Ipp, and the like, may be used to direct high levels of transcription of adjacent DNA segments.
  • trp-lac ⁇ JV5 (tac) promoter or other E. coli promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted gene.
  • Common promoters suitable for directing expression in mammalian cells include, without limitation, SV40, MMTV, metallothionein-1, adenovirus Ela, CMV, immediate early, immunoglobulin heavy chain promoter and enhancer, and RSV-LTR.
  • Mammalian cells that may be used for manufacture of the recombinant protein of the present invention include, for example, Chinese Hamster Ovary (CHO) cells, plant cells, chicken eggs, and human fibroblasts.
  • nucleic acid construct there are other specific initiation signals required for efficient gene transcription and translation in prokaryotic cells that can be included in the nucleic acid construct to maximize peptide production.
  • suitable transcription and/or translation elements including constitutive, inducible, and repressible promoters, as well as minimal 5 ' promoter elements, enhancers or leader sequences may be used.
  • a nucleic acid molecule encoding a recombinant protein of the present invention, a promoter molecule of choice, including, without limitation, enhancers, and leader sequences; a suitable 3 ' regulatory region to allow transcription in the host, and any additional desired components, such as reporter or marker genes, are cloned into the vector of choice using standard cloning procedures in the art, such as described in Joseph Sambrook et al, MOLECULAR CLONING: A LABORATORY MANUAL (Cold Springs Harbor 1989); Frederick M. Ausubel, SHORT PROTOCOLS IN MOLECULAR BIOLOGY (Wiley 1999), and U.S. Patent No. 4,237,224 to Cohen and Boyer, which are hereby incorporated by reference in their entirety.
  • nucleic acid molecule encoding the peptide Once the nucleic acid molecule encoding the peptide has been cloned into an expression vector, it is ready to be incorporated into a host. Recombinant molecules can be introduced into cells, without limitation, via transfection (if the host is a eukaryote), transduction, conjugation, mobilization, or electroporation, lipofection, protoplast fusion, mobilization, or particle bombardment, using standard cloning procedures known in the art, as described by JOSEPH SAMBROOK et al, MOLECULAR CLONING: A LABORATORY MANUAL (Cold Springs Harbor 1989), which is hereby incorporated by reference in its entirety.
  • host-vector systems include, without limitation, the following: bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA; microorganisms such as yeast containing yeast vectors; mammalian cell systems infected with virus (e.g. , vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); and plant cells infected by bacteria.
  • Purified peptides may be obtained by several methods readily known in the art, including ion exchange chromatography, hydrophobic interaction chromatography, affinity chromatography, gel filtration, and reverse phase chromatography.
  • the peptide is preferably produced in purified form (preferably at least about 80% or 85% pure, more preferably at least about 90% or 95% pure) by conventional techniques. Depending on whether the recombinant host cell is made to secrete the peptide into growth medium (see U.S. Patent No.
  • the peptide can be isolated and purified by centrifugation (to separate cellular components from supernatant containing the secreted peptide) followed by sequential ammonium sulfate precipitation of the supernatant.
  • cells may be transformed with DNA encoding AC and then cultured under conditions effective to produce the medium containing inactive AC precursor.
  • the fraction containing the peptide is subjected to gel filtration in an appropriately sized dextran or polyacrylamide column to separate the peptides from other proteins. If necessary, the peptide fraction may be further purified by other chromatography.
  • the incubation is carried out under conditions effective to reduce the transformation rate of inactive AC precursor to active AC compared to the transformation rate achieved when said incubating is carried out at a pH of 4 and a temperature of 4°C or 37°C, for 24 hours, under otherwise consistent conditions.
  • the incubating may be carried out under conditions effective to enhance the transformation rate of inactive AC precursor to active AC compared to those same conditions.
  • the ceramidase mixture during the incubating may have a pH over 4.0 and up to 6.5.
  • the mixture may, for example, have a pH of 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5.
  • the temperature of the ceramidase mixture during said incubating may be at least -30 °C and under 37 °C.
  • the temperature of the mixture may, for example, be - 30 °C, -25 °C, -20 °C, -15 °C, -10 °C, -5 °C, 0 °C, 5 °C, 10 °C, 15 °C, 20 °C, 25 °C, 30 °C, or 35 °C.
  • the mixture may be incubated under conditions of -30 °C with a pH of 4.0, 4 °C with a pH of 4.0 or 6.5, 25 °C with a pH of 4.0, or 37 °C with a pH of 4.0.
  • the mixture may be incubated for a period of time such as, but not limited to, approximately 30 minutes, 1 hour, 3 hours, 30 hours, or 300 hours.
  • the medium may be heated under conditions effective to remove acid sphingomyelinase activity.
  • the medium may be heated to 60 °C for a period of time including, but not limited to, less than 20 minutes, 20-40 minutes, 40-60 minutes, or more than 60 minutes.
  • Articular Chondrocytes Equal amounts of Lot 6 and Lot 7 rAC were added to the media of primary articular chondrocytes isolated from femurs. Cartilage was digested and cells were placed into culture with and without rAC supplementation. After three days the media was changed to media without rAC. Cells were grown for an additional two weeks and the levels of collagen 2 (marker of mature articular chondrocytes) was determined by western blotting.
  • Figure IB summarizes results for ability to form healthy mouse embryos in Lot 6 and Lot 7.
  • Lot 7 (containing more active rAC) produced more apoptotic embryos than lot 6 (containing less active rAC).
  • the preparation with less active enzyme (Lot 6) provided better results in IVF (fewer apoptotic embryos). This was unexpected.
  • Lot 6 and Lot 7 were also tested using cultured rat chondrocytes (Figure 1C). At two weeks the amount of collagen 2 expression was analyzed using western blotting. Cells cultured with Lot 7 (more active rAC) produced less collagen 2. Lot 6 was better in maintaining the chondrocyte phenotype after expansion ( Figure 1C, based on the expression of collagen 2). This was unexpected.
  • An important variable here is temperature. If the preparations are maintained (pH adjusted) frozen, there is no conversion. If the preparations are maintained at 4°C (in a refrigerator) the conversion proceeds but at 1% the efficiency of 37°C (10% increase in active enzyme requires 300 versus 3 hours). If the preparation is maintained at room temperature (25°C), it proceeds at 10%> the efficiency (10%> increase requires 30 hours). If the pH is not acidified, there is no conversion at 4°C and only 1% conversion rate (300 hours are required for an increase of 10%) at room temperature.
  • ASM acid sphingomyelinase activity
  • Conditioned media (DMEM, pH 6.8 containing 10% fetal calf serum) was collected from Chinese hamster ovary cells overexpressing and secreting recombinant human acid ceramidase (rhAC) (He et al., "Purification and Characterization of Recombinant, Human Acid Ceramidase. Catalytic Reactions and Interactions With Acid Sphingomyelinase," J. Biol. Chem. 278:32978-32986 (2003), which is hereby incorporated by reference in its entirety). The cells were grown until -100% confluency in T-75mm flasks, and media was then collected after 4 days of additional growth.
  • rhAC human acid ceramidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
PCT/US2014/026481 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them WO2014160390A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
ES14775400T ES2739811T3 (es) 2013-03-14 2014-03-13 Composiciones terapéuticas de ceramidasa ácida y métodos de fabricación y uso de ellas
PL14775400T PL2968479T3 (pl) 2013-03-14 2014-03-13 Kompozycje terapeutyczne ceramidazy kwasowej i sposoby ich wytwarzania i stosowania
EP14775400.6A EP2968479B1 (en) 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them
JP2016502154A JP6832158B2 (ja) 2013-03-14 2014-03-13 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
BR112015024538-2A BR112015024538B1 (pt) 2013-03-14 2014-03-13 Composição terapêutica de ceramidase ácida e seu método de produção
DK14775400.6T DK2968479T3 (da) 2013-03-14 2014-03-13 Terapeutiske sure ceramidasesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
CA2905449A CA2905449A1 (en) 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them
MX2015012471A MX2015012471A (es) 2013-03-14 2014-03-13 Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.
EP19183045.4A EP3659619A1 (en) 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them
US14/776,442 US9937246B2 (en) 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them
IL241390A IL241390B (en) 2013-03-14 2015-09-09 Therapeutic compounds containing acid ceramidase and methods for their production and use
HK16108585.6A HK1220399A1 (zh) 2013-03-14 2016-07-19 具有治療作用的酸性神經酰胺酶組合物及其製備和使用方法
US15/909,609 US10238721B2 (en) 2013-03-14 2018-03-01 Therapeutic acid ceramidase compositions and methods of making and using them
US16/271,433 US10918702B2 (en) 2013-03-14 2019-02-08 Therapeutic acid ceramidase compositions and methods of making and using them
HRP20191361 HRP20191361T1 (hr) 2013-03-14 2019-07-29 Pripravci ceramidaze terapeutske kiseline i postupci njihove izrade i uporabe
IL272214A IL272214B (en) 2013-03-14 2020-01-23 Therapeutic compounds containing acid ceramidase and methods for their production and use
IL288427A IL288427A (en) 2013-03-14 2021-11-25 The therapeutic compounds of the mechylum acid ceramidase and methods for their production and use
IL304629A IL304629A (en) 2013-03-14 2023-07-20 Acidic ceramidase mechyclom therapeutic compounds and methods for their production and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784594P 2013-03-14 2013-03-14
US61/784,594 2013-03-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/776,442 A-371-Of-International US9937246B2 (en) 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them
US15/909,609 Continuation US10238721B2 (en) 2013-03-14 2018-03-01 Therapeutic acid ceramidase compositions and methods of making and using them

Publications (1)

Publication Number Publication Date
WO2014160390A1 true WO2014160390A1 (en) 2014-10-02

Family

ID=51625420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/026481 WO2014160390A1 (en) 2013-03-14 2014-03-13 Therapeutic acid ceramidase compositions and methods of making and using them

Country Status (14)

Country Link
US (3) US9937246B2 (es)
EP (2) EP2968479B1 (es)
JP (4) JP6832158B2 (es)
CA (1) CA2905449A1 (es)
DK (1) DK2968479T3 (es)
ES (1) ES2739811T3 (es)
HK (1) HK1220399A1 (es)
HR (1) HRP20191361T1 (es)
HU (1) HUE046113T2 (es)
IL (4) IL241390B (es)
MX (2) MX2015012471A (es)
PL (1) PL2968479T3 (es)
PT (1) PT2968479T (es)
WO (1) WO2014160390A1 (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492514B2 (en) 2012-06-01 2016-11-15 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
US9655953B2 (en) 2004-07-01 2017-05-23 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046113T2 (hu) * 2013-03-14 2020-02-28 Icahn School Med Mount Sinai Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai
WO2018132667A1 (en) 2017-01-13 2018-07-19 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating farber disease
RU2020118032A (ru) * 2018-02-02 2022-03-02 Асераген, Инк. Способы лечения болезни фарбера
BR112020016435A2 (pt) * 2018-03-27 2020-12-15 Enzyvant Therapeutics Gmbh Marcadores de doença de farber e usos dos mesmos
EP3813871A4 (en) * 2018-06-29 2022-10-12 Icahn School of Medicine at Mount Sinai SPHINGOLIPID METABOLIZING PROTEINS ENCODING FOR ANC80
WO2020152532A1 (en) 2019-01-23 2020-07-30 Enzyvant Therapeutics Gmbh Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5653996A (en) 1993-06-30 1997-08-05 Genentech, Inc. Method for preparing liposomes
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6596509B1 (en) 1998-07-10 2003-07-22 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type III secretion systems
WO2008086296A2 (en) * 2007-01-05 2008-07-17 Mount Sinai School Of Medicine Acid ceramidase and cell survival
WO2011025996A2 (en) * 2009-08-28 2011-03-03 Mount Sinai School Of Medicine Of New York University Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US20110091439A1 (en) * 2007-12-18 2011-04-21 L'oreal Cosmetic use of acid ceramidase type proteins
WO2012154794A2 (en) * 2011-05-10 2012-11-15 Advanced Liquid Logic, Inc. Enzyme concentration and assays
WO2013036875A1 (en) * 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH585793A5 (es) 1974-02-01 1977-03-15 Nestle Sa
JPS5322158B2 (es) 1974-05-02 1978-07-06
IT1130242B (it) 1980-02-01 1986-06-11 Anic Spa Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5382524A (en) 1990-10-24 1995-01-17 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-n-acetylgalactosaminidase
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5433946A (en) 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
WO1994015578A1 (en) 1992-12-30 1994-07-21 George Joe Revis Anticaries compositions
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
DE69835367T2 (de) 1997-10-29 2007-08-02 Genzyme Corp., Framingham Gentherapie für gaucher-krankheit
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US7018628B1 (en) 1998-07-24 2006-03-28 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
US6258581B1 (en) 1998-08-20 2001-07-10 Takara Shuzo Co., Ltd. Ceramidase gene
GB9909064D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
US6730297B1 (en) 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6767741B1 (en) 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
IL149093A0 (en) 1999-10-13 2002-11-10 Yeda Res & Dev Short segments of dap-kinase
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
US7850984B2 (en) 2000-02-15 2010-12-14 The General Hospital Corporation Protection of the female reproductive system from natural and artificial insults
WO2001077307A2 (en) 2000-04-06 2001-10-18 Exegenics, Inc. Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2002051439A2 (en) 2000-12-22 2002-07-04 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US20020142299A1 (en) 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
EP1234816B1 (de) 2001-02-23 2004-06-30 Biofrontera Pharmaceuticals GmbH Scyphostatin-Analoga als SMase-Inhibitoren
ES2300439T3 (es) 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
JP2005515777A (ja) 2002-01-25 2005-06-02 ジェンザイム・コーポレーション 軟骨細胞のための無血清培地およびその使用法
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
DE10239531A1 (de) 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
EP1431399A1 (en) 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
ES2371913T3 (es) 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
CN105316405A (zh) 2003-07-17 2016-02-10 环太平洋生物技术有限公司 用于胃癌检测的标记物
WO2006113289A2 (en) 2005-04-19 2006-10-26 Vermillion, Inc. Saposin d and fam3c are biomarkers for alzheimer's disease
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US7273756B2 (en) 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US8017394B2 (en) 2004-10-01 2011-09-13 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
WO2006050265A2 (en) 2004-10-29 2006-05-11 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
US20070162992A1 (en) 2006-01-09 2007-07-12 Mcgill University Metabolomic determination in assisted reproductive technology
JP2009524829A (ja) 2006-01-27 2009-07-02 イースタン バージニア メディカル スクール ヒトｉｖｆ由来胚のプロテオームフィンガープリンティング：発生能のバイオマーカーの同定法
WO2007095688A1 (en) 2006-02-23 2007-08-30 The Australian National University Methods for increasing the number of circulating cells
AU2007241622A1 (en) 2006-04-24 2007-11-01 Academisch Medisch Centrum Improved treatment of cystic fibrosis
WO2007136635A1 (en) 2006-05-16 2007-11-29 Musc Foundation For Research Development Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators
EP2030025A2 (en) 2006-06-07 2009-03-04 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
WO2007149328A1 (en) 2006-06-20 2007-12-27 Genzyme Corporation Serum-free media and their uses for chondrocyte expansion
PL2132562T3 (pl) 2007-04-06 2012-06-29 Genzyme Corp Sposób oceniania komórek i hodowli komórkowych
WO2008148063A1 (en) 2007-05-24 2008-12-04 The Regents Of The University Of California Intranuclear protein transduction through a nucleoside salvage pathway
PT2164501E (pt) 2007-05-31 2016-06-02 Paradigm Biopharmaceuticals Ltd Xilanos sulfatados para tratamento ou profilaxia de doenças respiratórias
DE102007063535A1 (de) 2007-12-21 2009-06-25 Cycnad Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose
CA2728363C (en) 2008-06-26 2019-02-19 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
US20100068302A1 (en) 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
JP5721631B2 (ja) 2008-11-06 2015-05-20 ムスク ファウンデーション フォー リサーチ デベロップメント 酸性セラミダーゼのリソソーム親和性阻害剤
US20120115158A1 (en) 2009-05-01 2012-05-10 Mount Sinai School Of Medicine Method to determine embryo and oocyte quality based on ceramidase
HUE028129T2 (en) 2009-10-19 2016-11-28 Amicus Therapeutics Inc New preparations for the prevention and / or treatment of lysosomal storage disorders
PL3133070T3 (pl) 2009-11-27 2020-01-31 Genzyme Corporation Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
WO2012051415A2 (en) 2010-10-13 2012-04-19 Mount Sinai School Of Medicine Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies
WO2013101276A2 (en) 2011-04-01 2013-07-04 Mount Sinai School Of Medicine Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway
CN103764824B (zh) 2011-06-20 2018-04-24 西奈山医学院 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法
CA2874146C (en) * 2012-06-01 2023-03-21 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
US9341787B2 (en) 2013-01-02 2016-05-17 Micron Technology, Inc. Apparatus providing simplified alignment of optical fiber in photonic integrated circuits
HUE046113T2 (hu) * 2013-03-14 2020-02-28 Icahn School Med Mount Sinai Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5653996A (en) 1993-06-30 1997-08-05 Genentech, Inc. Method for preparing liposomes
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US6596509B1 (en) 1998-07-10 2003-07-22 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type III secretion systems
WO2008086296A2 (en) * 2007-01-05 2008-07-17 Mount Sinai School Of Medicine Acid ceramidase and cell survival
US20110091439A1 (en) * 2007-12-18 2011-04-21 L'oreal Cosmetic use of acid ceramidase type proteins
WO2011025996A2 (en) * 2009-08-28 2011-03-03 Mount Sinai School Of Medicine Of New York University Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
WO2012154794A2 (en) * 2011-05-10 2012-11-15 Advanced Liquid Logic, Inc. Enzyme concentration and assays
WO2013036875A1 (en) * 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation

Non-Patent Citations (56)

* Cited by examiner, † Cited by third party
Title
ARORA ET AL.: "Ceramide Induces Hepatocyte Cell Death Through Disruption of Mitochondrial Function in the Rat", HEPATOL, vol. 25, 1997, pages 958 - 63
BANGHAM ET AL.: "Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids", J. MOL. BIOL., vol. 13, 1965, pages 238 - 52, XP008039387, DOI: doi:10.1016/S0022-2836(65)80093-6
BECKER ET AL.: "Acid Sphingomyelinase Inhibitors Normalize Pulmonary Ceramide and Inflammation in Cystic Fibrosis", AM. J. RESPIR. CELL. MOL. BIOL., vol. 42, 2010, pages 716 - 724, XP055241100, DOI: doi:10.1165/rcmb.2009-0174OC
BERNARDO ET AL.: "Purification, Characterization, and Biosynthesis of Human Acid Ceramidase", J. BIOL. CHEM., vol. 270, 1995, pages 11098 - 102, XP000941304, DOI: doi:10.1074/jbc.270.19.11098
BERNARDO ET AL.: "Purification, Characterization, and Biosynthesis of Human Acid Ceramidase", J. BIOL. CHEM., vol. 270, 1995, pages 11098 - 11102, XP000941304, DOI: doi:10.1074/jbc.270.19.11098
CHAN; GOLDKORN: "Ceramide Path in Human Lung Cell Death", AM. J. RESPIR. CELL MOL. BIOL., vol. 22, no. 4, 2000, pages 460 - 8, XP003019071
CUVILLIER ET AL.: "Suppression of Ceramide-mediated Programmed Cell Death by Sphingosine-1-phosphate", NATURE, vol. 381, 1996, pages 800 - 3, XP002183247, DOI: doi:10.1038/381800a0
DE CASTRO E PAULA ET AL.: "Ceramide Inhibits Development and Cytokinesis and Induces Apoptosis in Preimplantation Bovine Embryos", MOL. REPROD. DEVEL., 2007
ELIYAHU ET AL.: "Acid Ceramidase Improves the Quality of Oocytes and Embryos and the Outcome of In Vitro Fertilization", FASEB J., vol. 24, 2010, pages 1229 - 1238, XP002595898, DOI: doi:10.1096/FJ.09-145508
FERLINZ ET AL.: "Human Acid Ceramidase: Processing, Glycosylation, and Lysosomal Targeting", J. BIOL. CHEM., vol. 276, no. 38, 2001, pages 35352 - 60
FREDERICK M. AUSUBEL: "SHORT PROTOCOLS IN MOLECULAR BIOLOGY", 1999, WILEY
GATT: "Enzymatic Hydrolysis of Sphingolipids. 1. Hydrolysis and Synthesis of Ceramides by an Enzyme from Rat Brain", J. BIOL. CHEM., vol. 241, 1966, pages 3724 - 31
GATT: "Enzymic Hydrolysis and Synthesis of Ceramide", J. BIOL. CHEM., vol. 238, 1963, pages 3131 - 3
GOMBOS ET AL.: "Cholesterol and Sphingolipids as Lipid Organizers of the Immune Cells' Plasma Membrane: Their Impact on the Functions of MHC Molecules, Effector T-lymphocytes and T-cell Death", IMMUNOL. LETT., vol. 104, no. 1-2, 2006, pages 59 - 69, XP024999214, DOI: doi:10.1016/j.imlet.2005.11.021
HANNUN: "Function of Ceramide in Coordinating Cellular Responses to Stress", SCIENCE, vol. 274, 1996, pages 1855 - 9
HASSLER ET AL.: "Ceramidases: Enzymology and Metabolic Roles", ADV. LIPID RES., vol. 26, 1993, pages 49 - 57
HASSLER; BELL: "Ceramidase: Enzymology and Metabolic Roles", ADV. LIP. RES., vol. 26, 1993, pages 49 - 57
HE ET AL., ANAL BIOCHEM, vol. 274, 1999, pages 264
HE ET AL.: "Purification and Characterization of Recombinant, Human Acid Ceramidase", J. BIOL. CHEM., vol. 278, 2003, pages 32978 - 32986
HE ET AL.: "Purification and Characterization of Recombinant, Human Acid Ceramidase. Catalytic Reactions and Interactions With Acid Sphingomyelinase", J. BIOL. CHEM., vol. 278, 2003, pages 32978 - 32986
HE, X ET AL.: "Purification And Characterization Of Recombinant, Human Acid Ceramidase: Catalytic Reactions And Interactions With Acid Sphingomyelinase.", J BIOL CHEM., vol. 278, no. 35, 29 August 2003 (2003-08-29), pages 32978 - 32986 *
HUANG, Y ET AL.: "Elevation Of The Level And Activity Of Acid Ceramidase In Alzheimer's Disease Brain.", EUR J NEUROSCI., vol. 20, no. 12, December 2004 (2004-12-01), pages 3489 - 3497 *
JOSEPH SAMBROOK ET AL.: "MOLECULAR CLONING: A LABORATORY MANUAL", 1989, COLD SPRINGS HARBOR
KOCH ET AL.: "Molecular Cloning and Characterization of a Full-Length Complementary DNA Encoding Human Acid Ceramidase. Identification Of the First Molecular Lesion Causing Farber Disease", J. BIOL. CHEM., vol. 271, 1996, pages 33110 - 33115, XP002152787, DOI: doi:10.1074/jbc.271.51.33110
KOCH ET AL.: "Molecular Cloning and Characterization of a Full-length Complementary DNA Encoding Human Acid Ceramidase. Identification of the First Molecular Lesion Causing Farber Disease", J. BIOL. CHEM., vol. 2711, 1996, pages 33110 - 5, XP002152787, DOI: doi:10.1074/jbc.271.51.33110
LANG ET AL.: "Mechanisms of Suicidal Erythrocyte Death", CELL. PHYSIOL. BIOCHEM., vol. 15, 2005, pages 195 - 202
LEE; AMOSCATO: "TRAIL and Ceramide", VITAM. HORM., vol. 67, 2004, pages 229 - 55
LI ET AL.: "Cloning and Characterization of the Full-length cDNA and Genomic Sequences Encoding Murine Acid Ceramidase", GENOMICS, vol. 50, 1998, pages 267 - 74, XP004449133, DOI: doi:10.1006/geno.1998.5334
LI ET AL.: "The Human Acid Ceramidase Gene (ASAH): Chromosomal Location, Mutation Analysis, and Expression", GENOMICS, vol. 62, 1999, pages 223 - 31, XP004444726, DOI: doi:10.1006/geno.1999.5940
MACRAE ET AL.: "Ceramide Inhibition of Chondrocyte Proliferation and Bone Growth Is IGF-I Independent", J. ENDOCRINOL., vol. 191, no. 2, 2006, pages 369 - 77, XP055170500, DOI: doi:10.1677/joe.1.06958
MIZUSHIMA ET AL.: "Ceramide, a Mediator of Interleukin 1, Tumour Necrosis Factor a, as Well as Fas Receptor Signaling, Induces Apoptosis of Rheumatoid Arthritis Synovial Cells", ANN. RHEUM. DIS., vol. 57, 1998, pages 495 - 9
MIZUSHIMA ET AL.: "Ceramide, a Mediator of Interleukin 1, Tumour Necrosis Factor a, as Well as Fas Receptor Signalling, Induces Apoptosis of Rheumatoid Arthritis Synovial Cells", ANN. RHEUM. DIS., vol. 57, 1998, pages 495 - 9
NIKOLOVA-KARAKASHIAN ET AL.: "Ceramidases", METHODS ENZYMOL., vol. 311, 2000, pages 194 - 201
OBEID ET AL.: "Programmed Cell Death Induced by Ceramide", SCIENCE, vol. 259, 1993, pages 1769 - 71, XP000644459, DOI: doi:10.1126/science.8456305
PARK ET AL.: "Acid Ceramidase and Human Disease", BIOCHIM. PHIOPHYS. ACT., vol. 1758, 2006, pages 2133 - 2138, XP025062972, DOI: doi:10.1016/j.bbamem.2006.08.019
PARK, JH ET AL.: "Aci d Ceramidase And Human Disease.", BIOCHIM BIOPHYS ACTA, vol. 1758, no. 12, December 2006 (2006-12-01), pages 2133 - 2138 *
PARK; SCHUCHMAN: "Acid Ceramidase and Human Disease", BIOCHIM. BIOPHYS. ACTA, vol. 1758, no. 12, 2006, pages 2133 - 2138, XP025062972, DOI: doi:10.1016/j.bbamem.2006.08.019
PARRA ET AL.: "Changes in Mitochondrial Dynamics During Ceramide-induced Cardiomyocyte Early Apoptosis", CARDIOVASC. RES., 2007
RAMSUBIR, S ET AL.: "In Vivo Delivery Of Human Acid Ceramidase Via Cord Blood Transplantation And Direct Injection Of Lentivirus As Novel Treatment Approaches For Farber Disease.", MOL GENET METAB., vol. 95, no. 3, November 2008 (2008-11-01), pages 133 - 141, XP025546364, DOI: doi:10.1016/j.ymgme.2008.08.003 *
ROBERTS; LAUER: "Maximizing Gene Expression On a Plasmid Using Recombination In Vitro", METHODS IN ENZYMOLOGY, vol. 68, 1979, pages 473 - 82, XP001314595
ROTHER ET AL.: "Biosynthesis of Sphingolipids: Dihydroceramide and Not Sphinganine Is Desaturated by Cultured Cells", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 189, 1992, pages 14 - 20, XP024840167, DOI: doi:10.1016/0006-291X(92)91518-U
SAMADI: "Ceramide-induced Cell Death in Lens Epithelial Cells", MOL. VIS., vol. 13, 2007, pages 1618 - 26
SHIFFMANN ET AL.: "Inhibitors of Specific Ceramide Synthases", BIOCHIMIE, vol. 94, 2012, pages 558 - 565, XP028441211, DOI: doi:10.1016/j.biochi.2011.09.007
SHTRAIZENT ET AL.: "Autoproteolytic Cleavage and Activation of Human Acid Ceramidase", J. BIOL. CHEM., vol. 283, 2008, pages 11253 - 11259
SHTRAIZENT ET AL.: "Autoproteolytic Cleavage and Activation of Human Acid Ceramidase", J. BIOL. CHEM., vol. 283, no. 17, 2008, pages 11253 - 11259
SHTRAIZENT, N ET AL.: "Autoproteolytic Cleavage and Activation of Human Acid Ceramidase.", J. BIOL. CHEM., vol. 283, no. 17, 14 February 2008 (2008-02-14), pages 11253 - 11259 *
SIMONARO, C. M. ET AL.: "Acid Ceramidase Improves the Chondrogenic Phenotype of Primary and Mesenchymal Stem Cell -Derived Chondrocytes: Implications for Cartilage Repair.", OSTEOARTHRITIS AND CARTILAGE., vol. 19, no. S1, September 2011 (2011-09-01), pages S114 - S115 *
SIMONARO, C.M. ET AL.: "Acid Ceramidase Maintains The Chondrogenic Phenotype Of Expanded Primary Chondrocytes And Improves The Chondrogenic Differentiation Of Bone Marrow-Derived Mesenchymal Stem Cells.", PLOS ONE., vol. 8, no. 4, 26 April 2013 (2013-04-26), pages E62715 *
SPIEGEL ET AL.: "Signal Transduction Through Lipid Second Messengers", CURR. OPIN. CELL. BIOL., vol. 8, 1996, pages 159 - 67
SPIEGEL; MERRILL: "Sphingolipids Metabolism and Cell Growth Regulation", FASEB J., vol. 10, 1996, pages 1388 - 97
TEICHGRABER, V ET AL.: "Ceramide Accumulation Mediates Inflammation, Cell Death and Infection Susceptibility in Cystic Fibrosis.", NAT MED., vol. 14, no. 4, April 2008 (2008-04-01), pages 382 - 391, XP002565225, DOI: doi:10.1038/nm1748 *
WANG ET AL.: "pH-Sensitive Immunoliposomes Mediate Target-cell-specific Delivery and Controlled Expression of a Foreign Gene in Mouse", PROC. NAT'L ACAD. SCI. USA, vol. 84, 1987, pages 7851 - 5, XP002089781, DOI: doi:10.1073/pnas.84.22.7851
WOLFF ET AL.: "The Use of Monoclonal Anti-Thyl IgGl for the Targeting of Liposomes to AKR-A Cells in Vitro and in Vivo", BIOCHIM. BIOPHYS. ACTA, vol. 802, 1984, pages 259 - 73
YOUNG ET AL.: "Sphingolipids: Regulators of Crosstalk Between Apoptosis and Autophagy", J. LIPID RES., vol. 54, 2013, pages 5 - 19
YOUNG ET AL.: "Sphingolipids: Regulators of Crosstalk Between Apoptosis and Autophagy", J. LIPID. RES., vol. 54, 2013, pages 5 - 19
ZEIDAN ET AL.: "Molecular Targeting of Acid Ceramidase: Implications to Cancer Therapy", CURR. DRUG TARGETS, vol. 9, no. 8, 2008, pages 653 - 661, XP009113322, DOI: doi:10.2174/138945008785132358

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655953B2 (en) 2004-07-01 2017-05-23 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
US9492514B2 (en) 2012-06-01 2016-11-15 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
US10159724B2 (en) 2012-06-01 2018-12-25 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections

Also Published As

Publication number Publication date
DK2968479T3 (da) 2019-08-12
JP6832158B2 (ja) 2021-02-24
JP2023015402A (ja) 2023-01-31
IL241390B (en) 2020-03-31
US10918702B2 (en) 2021-02-16
IL272214A (en) 2020-03-31
EP3659619A1 (en) 2020-06-03
JP2021042227A (ja) 2021-03-18
US20190231857A1 (en) 2019-08-01
EP2968479A4 (en) 2016-07-27
CA2905449A1 (en) 2014-10-02
IL304629A (en) 2023-09-01
MX2022003486A (es) 2022-04-25
US20160038574A1 (en) 2016-02-11
ES2739811T3 (es) 2020-02-04
IL241390A0 (en) 2015-11-30
EP2968479A1 (en) 2016-01-20
IL272214B (en) 2022-01-01
HK1220399A1 (zh) 2017-05-05
JP6832386B2 (ja) 2021-02-24
PL2968479T3 (pl) 2019-10-31
BR112015024538A2 (pt) 2018-05-08
US9937246B2 (en) 2018-04-10
HUE046113T2 (hu) 2020-02-28
JP2019150042A (ja) 2019-09-12
EP2968479B1 (en) 2019-07-17
US20180193436A1 (en) 2018-07-12
US10238721B2 (en) 2019-03-26
MX2015012471A (es) 2016-08-03
IL288427A (en) 2022-01-01
JP2016520519A (ja) 2016-07-14
HRP20191361T1 (hr) 2019-11-01
PT2968479T (pt) 2019-08-07

Similar Documents

Publication Publication Date Title
US10918702B2 (en) Therapeutic acid ceramidase compositions and methods of making and using them
US20190321454A1 (en) Ceramidase and cell differentiation
AU2013282400B2 (en) Cells for producing recombinant iduronate-2-sulfatase
US20230272115A1 (en) Compositions and methods for enhancing donor oligonucleotide-based gene editing
US20230279440A1 (en) Methods to genetically modify cells for delivery of therapeutic proteins
JP3410103B2 (ja) シュワン細胞の分離および培養
EP3357489A1 (en) Mutated arylsulfatase a
US20230212613A1 (en) Methods for targeted insertion of exogenous sequences in cellular genomes
WO2019060837A1 (en) PROCESS FOR PRODUCING RECOMBINANT HUMAN ACID CERAMIDASE
BR112015024538B1 (pt) Composição terapêutica de ceramidase ácida e seu método de produção
WO2024044697A2 (en) Compositions and methods for treatment of fabry disease
CA3208535A1 (en) Mutated arylsulfatase a with increased stability

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14775400

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 241390

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2905449

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016502154

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/012471

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14776442

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2014775400

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015024538

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015024538

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150914